CAR-T cell therapy

Chimeric-Antigen-Rezeptor (CAR)-T cell therapy

At our center we offer treatment with CAR-T cells for children, adolescents and young adults (up to 25 years) with a CD-19 positive relapse of their leukemia after allogeneic stem cell transplantation.

In this complex cell therapy procedure, the patient's own white blood cells are removed by leukapheresis and T cells are isolated therefrom in the laboratory. These are genetically engineered using an inactive viral vector to express a so-called chimeric antigen receptor (CAR) on their cell surface, which targets the antigen CD19. Upon binding of these CAR-T cells to the CD19-bearing leukemic target cells, they are destroyed.

Before receiving the laboratory-produced and augmented CAR-T cells, the patient receives a lymphodepletion chemotherapy in order to ensure good starting conditions for CAR-T cell expansion in the body.